An observational study in COVID-19, sponsored by Euresist Network GEIE. Recruiting at 10 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by Euresist Network GEIE · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.
Among the 392 studies in COVID-19 with a site in Italy, this one is the 2nd largest by planned enrollment of the 238 observational ones that give a count, is one of 36 that started in 2022, is one of 238 observational ones, reaches primary completion later than 31 of the 45 other live ones, and was the 319th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Italy, United States, Brazil and 4 more countries
Ages 18–65
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18–99 · Women only
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Italy
Ages 18+ · Healthy volunteers
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 53 · Phase 3 53 · Phase 4 3
First in 2009; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 100 across the 153 interventional studies, 251 across the 238 observational. Of the 235 that completed or were terminated, 29 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 392 have an industry lead sponsor. The 10 most frequent:
Euresist Network GEIE is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Euresist Network GEIE has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05188612University of BolognaInternational Survey of Acute Coronavirus Syndromes-COVID-19 | 2026-12-31 |
| NCT06070961Fondazione Italiana Linfomi - ETSProspective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 392 studies in COVID-19 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The WP3 hospitalized cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data from hospitalized COVID-19 patients followed at 12 clinics from 11 countries from 4 continents. In a subset of patients, peripheral blood, viral isolates and/or viral sequences are collected for analysis in WP2 with regards to neutralising antibodies, cellular immunity and SARS-CoV-2 diagnostics. Data and results from analysis of biological material will be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on clinical outcome of viral variants / viral sequences as well as the vaccines used and the vaccination schedules.
Background: Since the start of the COVID-19 pandemic, novel SARS-CoV-2 variants of concern have emerged, some of which have become largely dominant including the B.1.1.7 (alpha), the B.1.617 (delta) and more recently the B.1.1.529 (omicron). The clinical implications of the different variants in unvaccinated and vaccinated persons are still not adequately characterized. The detailed understanding of the interplay between the variants, vaccine immune responses and disease severity is still scarce.
Study objectives:
Overall objectives are:
Specific objectives are:
Hospitalized adult (>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included.
Inclusion Criteria:
Exclusion Criteria: none
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hospitalized adult (\>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included. Having a signed informed consent when required by ethical approval
Other: standard of care
The patient will be treated following the satndard of care in the participating units
Severity of SARS-CoV-2 infection
This is currently being discussed, which classification system should be used. This will be harmonized to recommendations by the WHO/ISARIC or other source.
Time frame: through study completion, an average of 4 year
In-hospital mortality
YYYY-MM-DD or NA if discharged alive
Time frame: through study completion, an average of 4 year
ICU Admissions and Discharges
YYYY-MM-DD or NA if not ICU-admitted
Time frame: through study completion, an average of 4 year
Rate of Invasive and Non invasive mechanical ventilation
Yes/No/Unknown - If yes, duration of mechanical ventilation
Time frame: through study completion, an average of 4 year
Frequency and type of Renal replacement therapies (RRT, dialysis)
Yes/No/Unknown
Time frame: through study completion, an average of 4 year
Frequency of Blood transfusions
Yes/No/Unknown
Time frame: through study completion, an average of 4 year
Frequency of ECMO Frequency of ECMO
Yes/No/Unknown
Time frame: through study completion, an average of 4 year
Plan to share: Yes — The study is part of a project funded by the European Commission and the project agreement with the Commission affirms that the data and the results will be publi
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: AFTER THE STUDY END NO TIME LIMIT WAS FIXED
Access criteria: REQUEST TO THE STUDY COORDINATOR OR TO THE PROJECT PARTNERS
Data sharing details ↗ · eucareresearch.eu
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Oct 2026, 55 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 55 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Euresist Network GEIE